Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including one "Best of ASH" presentation on Waldenstrom's macroglobulinemia (WM). In total, 33 additional pre-clinical and non-clinical presentations provided new discoveries using ibrutinib; seven of these were oral presentations. The presentations further elucidated the mechanism of action of ibrutinib and its effect in the tumor microenvironment and provided data on quality of life changes. Results covered various B-cell malignancies: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), WM, and non-Hodgkin lymphoma (NHL).

"The breadth of data presented at ASH this year demonstrates the scientific community's interest in ibrutinib and builds on the clinical responses seen with ibrutinib as a backbone of combination therapy and as a single agent in multiple B-cell malignancies," said Jesse McGreivy, M.D., Chief Medical Officer, Pharmacyclics. "This year's data explain ibrutinib's effect on the quality of life for patients and build on impressive efficacy and safety results, independent of cytogenetic risk factors. We also now have long-term follow-up in CLL, which suggests continuation of the efficacy and a decrease in overall and severe adverse events."

Clinical Trial Presentation Highlights

Chronic Lymphocytic Leukemia

-POSTER PRESENTATION- Abstract #4163:
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibruti
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014 Research ... "Global IVD Market 2014-2018" report to their offering. ... IVDs are widely used to diagnose, monitor, and assess ... environment. IVD tests provide outcomes for earlier and more ... hospital stay, and provide accurate results. This kind of ...
(Date:7/22/2014)... England , July 22, 2014 Elekta ... announced today that The Christie NHS Foundation Trust ( ... will join a consortium whose mission is to develop ... (MRI) guided radiation therapy system. Such a system would, ... visualization of cancer targets. "The Christie ...
(Date:7/22/2014)... Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... today that the U.S. Food and Drug Administration, or ... application.  Such clearance will permit Galmed to conduct clinical ... the United States for the treatment of ...
Breaking Medicine Technology:Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4
... , ENGLEWOOD, Colo., Dec. 7 Baxa Corporation is ... week,s ASHP Midyear Clinical Meeting (MCM). DoseEdge is a ... efficiency through the management of IV and oral dose ... practice and techniques, while providing a framework for reducing ...
... Dec. 7 Genoptix, Inc. (Nasdaq: GXDX ), a ... the Deutsche Bank 2009 MedTools Investor Conference to be held ... 2009. , Genoptix,s EVP and COO, Sam Riccitelli, ... December 9, 2009. He will provide an overview of ...
Cached Medicine Technology:Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2
(Date:7/22/2014)... of Hematology (ASH) will honor Michael DeBaun, MD, MPH, ... Hebbel, MD, of the University of Minnesota Medical School ... their significant research advances in the area of sickle ... the late Ernest Beutler, MD, a past president of ... a two-part lectureship that recognizes major translational advances related ...
(Date:7/22/2014)... American Society of Hematology (ASH) will present the Society,s ... Lifetime Achievement in Hematology, to Kanti R. Rai, MD, ... of Medicine for his 50-year career combining landmark clinical ... exceptional patient care. , The Wallace H. Coulter ... an individual who has been a vital contributor to ...
(Date:7/22/2014)... on cholesterol treatment and cardiovascular risk assessment state that ... from atherosclerotic cardiovascular disease or of having a heart ... risk profile (based on age, smoking history, and cholesterol ... for when and how aggressively to treat high cholesterol ... Men,s Health , a peer-reviewed publication from Mary Ann ...
(Date:7/22/2014)... 22, 2014 The Entertainment Industries Council, ... resources, educational tools and recognition activities for thousands of ... prevention, treatment and recovery. On July 24, 2014, at ... some of these resources with a special mention of ... and treatment website at the end of the show. ...
(Date:7/22/2014)... --,High school lacrosse players are facing an increasing number ... new study finds. Although the most common injuries ... concussions, researchers report. They note a better understanding of ... ways to protect student athletes. "Concern over concussions ... to learn more about these injuries," said study co-author ...
Breaking Medicine News(10 mins):Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 3
... DALLAS, Nov. 21 Susan G. Komen for ... for breast cancer research and,community-based outreach programs, is ... students who lost a,parent to breast cancer., ... Scholarship Award helps students cover the costs of,tuition, ...
... Nov. 21 Inverness Medical,Innovations, Inc. (Amex: IMA ... offering on Tuesday. The Company sold a total,of 13,634,302 ... of $61.49,per share. The total number of shares sold ... upon their exercise of their,over-allotment option in full. Certain ...
... and often deadly among older American women, doctors too ... a new report by a team of vascular surgeons ... Medical College campuses of NewYork-Presbyterian Hospital. , Much of ... cardiovascular research has focused almost exclusively on males, so ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... Executive Officer, will present at the Piper,Jaffray Health ... 28, 2007 at 1:00,p.m. Eastern Time., To ... the,presentation, visit the Investor Relations section of Genomic ...
... Ore., Nov. 21 ,Danaher Corporation (NYSE: DHR ) ... the expiration, as of 11:59 PM, New York City ... in the tender offer,made by Raven Acquisition Corp., Danaher,s ... of Tektronix, Inc. common,stock. The initial tender offer period ...
... plans that give best value for money, study finds , ... aren,t implementing strategies and programs to improve the quality and ... in the Nov. 21 issue of the Journal of ... Health researchers surveyed 609 executives of the largest employers ...
Cached Medicine News:Health News:Susan G. Komen for the Cure Provides Scholarships for Students Who Lost a Parent to Breast Cancer 2Health News:Inverness Medical Innovations Announces Closing of Public Offering 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 3Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 4Health News:Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 2Health News:Danaher Closes Subsequent Offering Period for Tektronix; Acquires Over 90% of TEK Shares 2Health News:Most U.S. Companies Do Little to Boost Worker Health Benefits 2
... practical, comfortable chair for examination ... height is adjustable from 540 ... use of an independent foot ... through 360 and incorporates a ...
... Halogen HPX Streak Retinoscope ... handle and provides 40% ... conventional scopes and maintains ... which greatly enhances illumination ...
Sandown chair, with hydraulic lift, sliding headrest and armrests with glides. Black vinyl....
3.5v Halogen HPX Spot Retinoscope provides 40% more light output than conventional scopes and maintains a consistent output level which greatly enhances illumination and produces the sharpest retina...
Medicine Products: